Johnson & Johnson to acquire Firefly Bio for $1 billion in cash, adding KRAS-focused degrader antibody conjugate platform to oncology pipeline
https://finviz.com/stock?t=JNJ&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.